Wall Street's major indexes ended higher on Friday (July 26) as investors flocked back to tech megacaps that had triggered broad sell-offs earlier in the week, and inflation data boosted optimism that the Federal Reserve will soon commence cutting interest rates.Regarding the options market, a total volume of 43,779,016 contracts was traded on Friday.Top 10 Option VolumesTop 10:$NVDA(NVDA)$; $TSLA(TSLA)$; $AAPL(AAPL)$; $AMD(AMD)$; $MSFT(MSFT)$; $AMZN(AMZN)$; $META(META)$;
Option Movers | Tesla to Drop Back to $200? Traders Bet Chewy up to $30
Market OverviewMegacap growth stocks led by Apple and Tesla lifted the tech-heavy Nasdaq to a higher close on Monday (July 1), while the Dow and the S&P 500 also eked out slight gains in light pre-holiday trading.Regarding the options market, a total volume of 37,987,662 contracts was traded, up 14% from the previous trading day.Top 10 Option VolumesTop 10: $NVDA(NVDA)$, $TSLA(TSLA)$, $AAPL(AAPL)$, $AMZN(AMZN)$, $AMD(AMD)$, $NKE(NKE)$, $MARA(MARA)$, $GME(
Option Movers | Microsoft's $430 Call Worth Attention As Stock Hits Record High; Adobe Shows Bearish Sentiment
U.S. stocks dropped on Thursday (Mar. 14th), with chipmaker stocks extending losses for a second day, and as a jump in producer prices left investors wondering if the Federal Reserve might wait longer than expected to cut interest rates.Regarding the options market, a total volume of 47,476,459 contracts was traded on Thursday.Top 10 Option VolumesTop 10: $SPY(SPY)$; $QQQ(QQQ)$; $TSLA(TSLA)$; $SPX(SPX)$; $NVDA(NVDA)$; $AAPL(AAPL)$; $VIX(VIX)$; $IWM(IWM)$; <
Biotech Industry Resurgence: Anticipating New Trends and Bright Prospects in 2024
The biotechnology industry is experiencing a revival, breaking free from a period of stagnation.Since reaching its peak in early 2021, the S&P Biotechnology Select Industry Index has lost over 50% of its value. The downturn can be attributed to rising interest rates and a slowdown in the success of the pandemic period, leading to a widespread pessimism among investors.Looking ahead to 2024, analysts anticipate a more favorable interest rate environment, increased deal activity, and innovations in critical areas such as cancer and immunology, brightening the prospects for biotechnology companies. The biotech industry's index has seen a 29% increase since the end of October.Merger and acquisition activities in the biotech industry are gaining momentum. According to PwC's latest analysis,
Top Calls on Wall Street: Apple, Microsoft, Amazon, Rivian, Broadcom and More
Here are Friday’s biggest calls on Wall Street:Bank of America reiterates Broadcom as buyBank of America raised its price target on the stock to $950 per share from $800 after Broadcom’s earnings report on Thursday. The firm said it’s an “underappreciated AI portfolio” story.“Our new PO of $950 (from $800) represents 21x CY24E EV/FCF as AI accelerates company growth potential. In a bull case scenario where AVGO can grow AI exposure to ~25% of sales we see incremental $2bn/$3 upside to our sales/EPS estimates..”B. Riley FBR initiates Bowlero as buyB. Riley said shares of the bowling company are attractive.“We believe Bowlero is well positioned to continue to take market share from a fragmented and ‘old school’ bowling industry with a management team that has a proven track record of value c
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
03-17 20:15
Annual Report
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]